US · Healthcare · Biotechnology
EPS came in at -2.87 against a street estimate of -3.60 — a beat of 20.3%.
Analysts rate Praxis Precision Medicines Inc a strong buy (17 buy, 1 hold, 1 sell out of 19) with an average price target of $644.42.
CONFIDENT Two NDAs in late FDA review with ~6-month approval timelines; $1.4B cash runway extends to 2028. Commercial infrastructure built; vormatrigine trial redesigned post-setback. Q2 2026 No geographic segment breakdown provided in call. Analysts focused on vormatrigine redesign feasibility, relutrigine efficacy heterogeneity, and ulixacaltamide tolerability-driven discontinuation. Management was disciplined: acknowledged design fixes are fixable, efficacy will vary by etiology, and commercial infrastructure directly addresses persistence via titration support and integrated pharmacy hub. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| HHG PLC | 12.39% |
| Jupiter Topco LLC | 12.25% |
| FMR Inc | 8.30% |
| BlackRock Inc | 8.21% |
| Perceptive Advisors LLC | 7.29% |
| Baker Bros Advisors LP | 6.28% |
| Orbis Allan Gray Ltd | 5.48% |
| Vanguard Portfolio Management, LLC | 4.78% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 PRAXIS PRECISION MEDICINES, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Investments: $1.374 billion (Cash: $474.8M + Marketable securities | 2026-08-06 |
| Results announced · Q3 2026 PRAXIS PRECISION MEDICINES Q2 2026 SUMMARY HEADLINE NUMBERS • Cash and investments: $1.4 billion as of June 30, 2026 (up from $926.1 million at Dece | 2026-08-06 |
| Company announcement · Q3 2026 PRAXIS PRECISION MEDICINES, INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company announced a research collaboration and license agreement | 2026-07-07 |
| Current report · Q2 2026 PRAXIS PRECISION MEDICINES, INC. – FORM 8-K SUMMARY OTHER NOTABLE POINTS • Auditor Change: Company dismissed Ernst & Young LLP (EY) as independent r | 2026-07-02 |
| Company announcement · Q2 2026 PRAXIS PRECISION MEDICINES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • FDA extended review period for relutrigine NDA by 3 months • New PDUFA target | 2026-06-29 |
| Quarterly report · Q1 2026 PRAXIS PRECISION MEDICINES, INC. - Q1 2026 SUMMARY HEADLINE NUMBERS • Cash & Investments Position: $1.4 billion total ($536.3 million cash + $911.5 | 2026-05-07 |
| Proxy statement · Q2 2026 PRAXIS PRECISION MEDICINES, INC. – 2026 PROXY SUMMARY --- CEO COMPENSATION & CHANGE • Marcio Souza (President and CEO) total compensation: Document | 2026-04-30 |
| Annual report FY2025 PRAXIS PRECISION MEDICINES, INC. – 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Company classified as large accelerated filer on Nasdaq (ticker: PRAX) | 2026-02-19 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 15 effective Nov 29, 2023 | 2023-11-29 |
| Announcement | Date |
|---|---|
| Research collaboration and license agreement with equity investment in Remagine Labs Praxis Precision Medicines announced a research collaboration with Remagine Labs to develop an iontophoretic transdermal patch (electronic patch) for delivering ulixacaltamide, the company's | 2026-07-07 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Praxis Precision Medicines Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.